News
Public · Published
Novo improves outlook on continued demand for Wegovy pill, Ozempic
Novo raised its full-year outlook again, saying sales and operating profit could range from a 2% decline to a 2% increase at constant exchange rates, compared with its previous forecast of declines of up to 6%. The company cited demand for Wegovy's weight-loss pill and Ozempic.
Published:
Updated:
What happened
Novo raised its full-year outlook again, saying sales and operating profit could range from a 2% decline to a 2% increase at constant exchange rates, compared with its previous forecast of declines of up to 6%. The company cited demand for Wegovy’s weight-loss pill and Ozempic.
Confirmed
Global impact / market context
A better outlook reflects stronger expected sales of Novo’s GLP-1 medicines, a class of drugs that includes Wegovy and Ozempic. If demand continues, revenue could support company results, while wider availability of the pill could help Novo compete for customers in obesity treatment.
Analyst inference
Novo’s third-quarter sales rose 6% year over year, but operating profit fell 3%; adjusted operating profit, which excludes certain items, rose 34%. The article describes competition with Eli Lilly and says oral weight-loss treatments have become an important battleground.
Confirmed
What to watch
- Whether Novo’s Wegovy pill becomes available in more than 20 markets next year, as planned, and whether broader access helps sustain the demand behind its improved outlook. Confirmed
- Whether demand for Wegovy and Ozempic remains strong enough to support sales, and whether the oral pill’s expansion changes Novo’s competitive position against Eli Lilly. Analyst inference
- How reported operating profit develops alongside adjusted operating profit, since the two measures moved in opposite directions in the third quarter. Analyst inference